Novartis lifts peak sales forecasts for three drugs to $18 billion

In a November 19, 2026, update, Novartis raised its combined peak sales forecast for three drugs—multiple sclerosis treatment Kesimpta, leukaemia treatment Scemblix and cholesterol medicine Leqvio—to $18 billion, from $14 billion.

CEO Vas Narasimhan attributed the increase mainly to commercial performance, citing growing market share for Kesimpta and Scemblix and strong demand for Leqvio in the U.S. and Asia.

The Swiss drugmaker projected annual sales growth of 5% through 2031. Its previous guidance was 5% to 6% through 2030, though the forecasts cover different five-year periods. Narasimhan said the revised outlook reflects expected U.S. generic competition for breast cancer treatment Kisqali in the second half of 2031.

Citi analysts said the 2031 sales guidance was about 3% above consensus, but expected investors to remain skeptical about growth after 2031 pending more pipeline data. Novartis shares fell 2.4% in mid-morning trading in Switzerland on November 19.

Recent trial failures have added to questions about the company’s growth strategy. In September 2026, a trial of cardiovascular drug pelacarsen failed to show improved cardiovascular outcomes. The following day, del-desiran, a treatment for a muscle-wasting disorder, failed in a late-stage trial; Novartis shares fell nearly 11%, their worst single-day drop since 1987. Novartis had acquired del-desiran through its $12 billion deal for Avidity Biosciences earlier in 2026.

Defending the company’s approach to acquisitions, Narasimhan said shareholders differed over dealmaking but that Novartis remained confident in its strategy. He cited a 275% total shareholder return over the preceding decade, which he said ranked the company among the sector’s top performers.

Further reading